Oestrogen reduces psychosis symptoms in women

In the first large-scale clinical trial of oestrogen in women with treatment-resistant schizophrenia, researchers from the Monash Alfred Psychiatry Research Centre randomised 180 women aged 18–45 into three groups: the first received 100mcg of transdermal oestradiol for eight weeks, the second received 200mcg and the third received a placebo patch.